Event Details

Event Details

Event Details

16th Clinical Trials on Alzheimer’s Disease (CTAD)

10/24/23 - 10/27/23

Webcast Presentation

Supporting Materials

Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study 3.1 MB

Title

16th Clinical Trials on Alzheimer’s Disease (CTAD)

Date / Time

10/24/23 - 10/27/23